Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P M Patel

Showing results (81-90 of 311) with videos related to

Pageof 32
Sort By:
British Journal of Cancer|August 1, 1993
Comparison of the potential therapeutic effects of interleukin 2 or interleukin 4 secretion by a single tumourP M Patel, C L Flemming, S J Russell, et al.
Spine|July 15, 1996
Myogenic motor-evoked potential monitoring using partial neuromuscular blockade in surgery of the spineE W Lang, A S Beutler, R M Chesnut, et al.
British Journal of Cancer|February 8, 2007
A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinomaD M Shaw, N B Connolly, P M Patel, et al.
British Journal of Cancer|December 6, 2006
A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanomaJ M G Larkin, S A Hughes, D A Beirne, et al.
British Journal of Anaesthesia|October 4, 2017
Inhibition of p75 neurotrophin receptor does not rescue cognitive impairment in adulthood after isoflurane exposure in neonatal miceJ M Schilling, A Kassan, C Mandyam, et al.
British Journal of Cancer|January 27, 2011
Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell linesM Z Mohammed, V N Vyjayanti, C A Laughton, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 2008
An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancerP M Patel, S Sim, D O O'Donnell, et al.
Cytokine|May 11, 2000
Subcutaneous administration of recombinant glycosylated interleukin 6 in patients with cancer: pharmacokinetics, pharmacodynamics and immunomodulatory effectsR E Banks, M A Forbes, P M Patel, et al.
British Journal of Urology|May 1, 1996
A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activationJ K Joffe, R E Banks, M A Forbes, et al.
Human Gene Therapy|March 1, 1997
Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin-2 induce CD4+-mediated rejection of established tumorsJ A Gaken, S J Hollingsworth, W J Hirst, et al.
Pageof 32

Showing results (81-90 of 311) with videos related to

Sort By:
Pageof 32
British Journal of Cancer|August 1, 1993
Comparison of the potential therapeutic effects of interleukin 2 or interleukin 4 secretion by a single tumourP M Patel, C L Flemming, S J Russell, et al.
Spine|July 15, 1996
Myogenic motor-evoked potential monitoring using partial neuromuscular blockade in surgery of the spineE W Lang, A S Beutler, R M Chesnut, et al.
British Journal of Cancer|February 8, 2007
A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinomaD M Shaw, N B Connolly, P M Patel, et al.
British Journal of Cancer|December 6, 2006
A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanomaJ M G Larkin, S A Hughes, D A Beirne, et al.
British Journal of Anaesthesia|October 4, 2017
Inhibition of p75 neurotrophin receptor does not rescue cognitive impairment in adulthood after isoflurane exposure in neonatal miceJ M Schilling, A Kassan, C Mandyam, et al.
British Journal of Cancer|January 27, 2011
Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell linesM Z Mohammed, V N Vyjayanti, C A Laughton, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 2008
An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancerP M Patel, S Sim, D O O'Donnell, et al.
Cytokine|May 11, 2000
Subcutaneous administration of recombinant glycosylated interleukin 6 in patients with cancer: pharmacokinetics, pharmacodynamics and immunomodulatory effectsR E Banks, M A Forbes, P M Patel, et al.
British Journal of Urology|May 1, 1996
A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activationJ K Joffe, R E Banks, M A Forbes, et al.
Human Gene Therapy|March 1, 1997
Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin-2 induce CD4+-mediated rejection of established tumorsJ A Gaken, S J Hollingsworth, W J Hirst, et al.
Pageof 32